Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEN-STEM
- Development stage
- Unknown
- Lead developer
- Oslo University Hospital
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
DEN-STEM is a personalized, trivalent dendritic cell (DC) vaccine developed by Oslo University Hospital for the treatment of glioblastoma. The therapy involves harvesting a patient's own monocytes via leukapheresis and differentiating them into dendritic cells *ex vivo*. These dendritic cells are then transfected with messenger RNA (mRNA) encoding three distinct sources of antigens: autologous tumor stem cells (derived from the patient's own tumorspheres), survivin (BIRC5), and human telomerase reverse transcriptase (hTERT). The engineered dendritic cells are administered via intradermal injection to activate the patient's immune system against glioblastoma. As potent antigen-presenting cells, the DCs present these tumor-associated antigens to T-cells, educating the immune system to recognize and attack the cancer stem cell population, which is believed to drive tumor progression and recurrence.
- Other names
- Trivalent dendritic cell vaccinemRNA-transfected dendritic cell immunotherapy
Beyond the preview
Go deeper on DEN-STEM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEN-STEM.